Abstract

Migraine is becoming to be recognized as one of the most significant health burden to people as well as one of the most challenging clinical problem to clinicians. Since the role of serotonin in the patho- genesis of migraine was established, there have been leaping advances in migraine therapy which were in conjunction with the advent of sumatriptan followed by various second generation triptans. Nowadays what agent clinicians should select in acute treatment of various migraines is changing in relation to such advances. In this review, the author described recent trends in acute migraine therapy with stress on evidence-based guideline for migraine headache published by the Quality Standards Subcommittee of the American Academy of Neurology in company with some remarks on the various triptans. Korean Journal of Headache 4(1):30-36, 2003